Literature DB >> 2240333

Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection.

R E Solomon1, M VanRaden, R A Kaslow, D Lyter, B Visscher, H Farzadegan, J Phair.   

Abstract

We examined the associations between seropositivity for hepatitis B virus (HBV) with the presence or development of antibodies to human immunodeficiency virus (HIV-1) and with HIV-1 induced T-helper lymphocyte deficiency or acquired immunodeficiency syndrome (AIDS). Serologic data on HBV and HIV-1, cytometric enumeration of CD4+ lymphocytes, clinical events (AIDS by Centers for Disease Control criteria) and hepatitis B vaccination histories were available on 4,498 homosexual participants in the Multicenter AIDS Cohort Study, Men were classified as to previous infection with HBV and prevalent or incident infection with HIV-1. Although there was an association between seropositivity for HBV infection and HIV-1 infection at enrollment (odds ratios anti-HBc 2.6; HBsAg 4.2), the relation between HBV seropositivity and subsequent seroconversion to HIV-1 was weaker (odds ratios 1.3 and 1.6). HIV-1 seroconversion was also associated with a history of certain other sexually transmitted diseases, but predisposing sexual practices did not account for the association between HBV and HIV-1 infection. Seropositivity for HBV infection at entry was not related to initially low or more rapid subsequent decline in T-helper lymphocyte counts and was not associated with an increased incidence of AIDS during 2.5 years of follow-up. History of vaccination against HBV did not appear to decrease susceptibility to HIV-1 infection or to subsequent progression of immunodeficiency. We conclude that prior HBV infection is unlikely to be specifically associated with acquisition of HIV-1 infection and is unrelated to more rapid progression of HIV-1-induced immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2240333      PMCID: PMC1405125          DOI: 10.2105/ajph.80.12.1475

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  14 in total

1.  Hepatitis B surface antigen could harbour the infective agent of AIDS.

Authors:  M I McDonald; J D Hamilton; D T Durack
Journal:  Lancet       Date:  1983-10-15       Impact factor: 79.321

2.  The Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody.

Authors:  E Jeffries; B Willoughby; W J Boyko; M T Schechter; B Wiggs; S Fay; M O'Shaughnessy
Journal:  Can Med Assoc J       Date:  1985-06-15       Impact factor: 8.262

3.  Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy.

Authors:  K H Mayer; D Ayotte; J E Groopman; A M Stoddard; M Sarngadharan; R Gallo
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

4.  Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study.

Authors:  J S Chmiel; R Detels; R A Kaslow; M Van Raden; L A Kingsley; R Brookmeyer
Journal:  Am J Epidemiol       Date:  1987-10       Impact factor: 4.897

5.  Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein.

Authors:  E Seto; T S Yen; B M Peterlin; J H Ou
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.

Authors:  R A Kaslow; D G Ostrow; R Detels; J P Phair; B F Polk; C R Rinaldo
Journal:  Am J Epidemiol       Date:  1987-08       Impact factor: 4.897

7.  Hepatitis B virus DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex.

Authors:  F Laure; D Zagury; A G Saimot; R C Gallo; B H Hahn; C Brechot
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

8.  Relationship between T cell subsets and suppressor cell activity in chronic hepatitis B virus (HBV) infection.

Authors:  V Barnaba; A Musca; C Cordova; M Levrero; G Ruocco; V Albertini-Petroni; F Balsano
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

9.  Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1.

Authors:  J S Twu; K Chu; W S Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

View more
  9 in total

1.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Authors:  Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias.

Authors:  Chanelle J Howe; Stephen R Cole; Joan S Chmiel; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2011-02-02       Impact factor: 4.897

Review 3.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 4.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

5.  Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection.

Authors:  T Wölfel; P Schirmacher; J Schlaak; P Knolle; H P Dienes; W Dippold; K H Meyer zum Büschenfelde; G Gerken
Journal:  Clin Investig       Date:  1994-12

6.  HIV outcomes in Hepatitis B virus coinfected individuals on HAART.

Authors:  Helen M Chun; Octavio Mesner; Chloe L Thio; Ionut Bebu; Grace Macalino; Brian K Agan; William P Bradley; Jennifer Malia; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Mary Bavaro; Jason D Maguire; Michael L Landrum
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

7.  GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals.

Authors:  Edgar T Overton; Somnuek Sungkanuparph; Michael Klebert; Michael Royal; Debra Demarco-Shaw; William G Powderly; Judith A Aberg
Journal:  Open Virol J       Date:  2011-10-14

8.  Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine.

Authors:  Neelam Pasricha; Usha Datta; Yogesh Chawla; Surjit Singh; Sunil K Arora; Archana Sud; Ranjana W Minz; Biman Saikia; Haqeeqat Singh; Isaac James; Shobha Sehgal
Journal:  BMC Infect Dis       Date:  2006-03-30       Impact factor: 3.090

Review 9.  The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature.

Authors:  Helen M Chun; Robert J Carpenter; Grace E Macalino; Nancy F Crum-Cianflone
Journal:  J Sex Transm Dis       Date:  2013-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.